IQVIA

Market Reflection Report

Jun 2023

10th July

© 2023. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States,
the European Union, and various other countries.
 IPM Overview
TSA SSA
Growth %%

80 60
60 2020-21
40
40 2021-22
20
20 2022-23
0 0
-20 -20
Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun

TSA IPM Trends (Value Rs. 204,745 Crs) – MAT Jun'23 SSA IPM Trends (Value Rs. 173,103 Crs) – MAT Jun'23

+4.5%
+4.0%
+10.6%
+10.3%
MAT
204,745 MAT
Month 173,103
185,199 Month
156,987
170,896
145,428
148,858
126,560

12,217 13,853 15,760 16,469 10,565 11,793 13,293 13,822

2020 2021 2022 2023 2020 2021 2022 2023

• TSA valued at Rs 16,469 Cr for Jun'23 month with growth of 4.5% and Rs. 204,745 Cr with growth of 10.6% as of MAT Jun’23
• SSA valued at Rs 13,822 Cr for Jun'23 month with growth of 4.0% and MAT was at Rs. 173,103 Cr with growth of 10.3%

IQVIA TSA & SSA Dataset Jun'23 1

 Cardiac and Derma posted 8% growth respectively
TSA

MOM Trend Gwth % (SPLY)

Value (Rs. Crs)

15 13 24 19
IPM 16,469 9 10 7 3 4 12 10 4 IPM
11 12 15 12 10 17 13 12
8 7 9 8
CARDIAC 2,107 Cardiac

13 15 13 11 24 15
11 2 6 6 5 3 Gastro
GASTRO 1,865
52 50
16 23 25
11 12 1 8
ANTI-INFECTIVES 1,590 -1 -2 -2
13
8 9 7 10 7 7 9 9 AI
3 5 6
ANTI DIABETIC 1,577 ADB
14 16
10 12
5 7 7 7 4
VMN 1,361 1 0 6 VMN
27 23
14 13 16 16 14 10
PAIN 1,322 9 5 5
1 Pain
13 11 12 11
DERMA 1,183 5 7 6 7 6 8
2 4 Derma
14 13 16
9 11 10 12 11 9 11
5 6
NEURO 1,030 Neuro
21 56 50 29
16 9 -8 2 16 -7 9 -6
RESPIRATORY 1,010
Respi
10 14 15 8 20 14 11 17 10 8
4 4 Gynae
GYNAEC. 910
Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun

Therapy sorted on Month

IQVIA TSA & SSA Dataset Jun'23 2

 Top Companies #1-10 Market Share Trend
9

Val Jun'23 MS Jun'23

8 (SUN*) 1,305 7.92%

ABBOTT* 1,056 6.41%

7 CIPLA 850 5.16%

(MANKIND) 702 4.26%

(ALKEM*) 645 3.92%

6
(LUPIN ) 572 3.47%
TORRENT 586 3.56%
5
(INTAS*) 602 3.65%
MACLEODS 524 3.18%
4 DRL 470 2.85%

2
Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’23 May’23 Jun’23

• Abbott*, Cipla, Torrent, Macleods & DRL have shown improvement in MS for Jun'23 as compared to May'23
• Sun*, Mankind, Alkem*, Lupin & Intas* have reflected dip in MS for Jun'23 as compared to May'23

IQVIA TSA & SSA Dataset Jun'23 3

 Top Companies #1-10
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

SUN* 1,305 6 101 SUN* 1,099 5 101

ABBOTT* 1,056 6 101 ABBOTT* 902 5 101
CIPLA 850 3 99 CIPLA 715 3 99
MANKIND 702 4 99 MANKIND 632 4 100
Month

Month
ALKEM* 645 2 98 ALKEM* 555 2 98
INTAS* 602 10 105 TORRENT 513 4 100
TORRENT 586 5 100 INTAS* 489 10 106

LUPIN 572 3 99 LUPIN 485 2 98

MACLEODS 524 7 102 MACLEODS 463 7 103

3 99 DRL 410 5 101
DRL 470

SUN* 15,714 11 101 SUN* 13,382 10 100

ABBOTT* 12,672 11 100 ABBOTT* 10,812 11 101
CIPLA 11,121 12 102 CIPLA 9,366 13 102
MANKIND 9,076 15 104 MANKIND 8,178 15 104
MAT

104 103

MAT
ALKEM* 8,319 15 ALKEM* 7,203 14
LUPIN 7,066 8 97 TORRENT 6,074 11 101
INTAS* 7,050 15 104 LUPIN 6,026 6 96
TORRENT 6,917 12 101 MACLEODS 6,008 14 104
MACLEODS 6,786 15 104 INTAS* 5,762 14 104
ARISTO* 5,963 11 100 ARISTO* 5,400 10 100

• TSA : Intas* has posted highest growth followed by Macleods on Month while on MAT, Mankind, Alkem*, Intas* & Macleods are the fastest growing

• SSA : Intas* has posted highest growth followed by Macleods on Month level, while on MAT level, Mankind has reflected the highest growth

IQVIA TSA & SSA Dataset Jun’23 4

 Top Companies #11-20 Market Share Trend
3.4

3.2
Val Jun'23 MS Jun'23
3.0
(ARISTO*) 445 2.70%
2.8
(ZYDUS*) 464 2.82%
2.6 (GSK*) 373 2.27%
2.4 (EMCURE*) 331 2.01%
2.2 GLENMARK 317 1.93%

2.0 USV 339 2.06%

(IPCA) 303 1.84%
1.8
(PFIZER*) 239 1.45%
1.6
MICRO* 262 1.59%
1.4
(SANOFI*) 256 1.55%
1.2

1.0

0.8

0.6
Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’23 May’23 Jun’23

• Glenmark & USV have shown improvement in MS for Jun'23 as compared to May’23
• Micro* have maintained MS in the month of Jun'23
• Aristo*, Zydus*, GSK*, Emcure*, IPCA, Pfizer* & Sanofi* have reflected dip in MS for Jun'23 as compared to May'23

IQVIA TSA & SSA Dataset Jun'23 5

 Top Companies #11-20
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

5 100 ARISTO* 401 2 98

ZYDUS* 464
2 98 ZYDUS* 374 4 100
ARISTO* 445
-1 94 USV 303 7 103
GSK* 373
7 103 GSK* 295 -1 95
USV 339
Month

Month
4 99 GLENMARK 279 9 105
EMCURE* 331
6 102 EMCURE* 270 3 99
GLENMARK 317
5 101 IPCA 257 4 100
IPCA 303
1 97 MICRO * 222 1 97
MICRO * 262
-1 95 ALEMBIC 202 3 100
SANOFI* 256
-10 86 PFIZER* 182 -10 87
PFIZER* 239

ZYDUS* 5,917 10 99 DRL 5,075 5 95

DRL 5,888 6 96 ZYDUS* 4,810 10 100
GSK* 5,179 8 98 GSK* 4,217 11 100
EMCURE* 4,168 8 98 GLENMARK 3,676 13 103
MAT

101 12 101

MAT
GLENMARK 4,165 12 USV 3,532
USV 3,964 11 101 EMCURE* 3,447 10 100
IPCA 3,791 13 102 IPCA 3,250 12 102
MICRO * 3,411 7 97 MICRO * 2,928 10 100
PFIZER* 3,291 0 90 ALEMBIC 2,795 11 100
SANOFI* 3,158 1 92 PFIZER* 2,558 1 92

• TSA : USV has posted the highest growth on month & for MAT, IPCA followed by Glenmark posted highest growth

• SSA : Glenmark has posted the highest growth on month level as well as MAT level

IQVIA TSA & SSA Dataset Jun’23 6

 Top Companies #21-30 Market Share Trend
1.7
Val Jun'23 MS Jun'23
1.6 227 1.38%
(ALEMBIC)
1.5 ERIS* 183 1.11%

(FDC) 179 1.09%

1.4
JB PHARMA* 179 1.09%
1.3
(HIMALAYA ) 132 0.80%
1.2 (CADILA) 123 0.75%

1.1 (FRANCO) 101 0.61%

AJANTA 131 0.80%

1.0
INDOCO* 96 0.58%
0.9 89 0.54%
(BLUE CROSS)
0.8

0.7

0.6

0.5
Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’23 May’23 Jun’23

• Eris*, JB Pharma*, Indoco* have shown improvement in MS for Jun'23 as compared to May’23
• Ajanta have maintained MS in the month of Jun'23
• Alembic, FDC, Himalaya, Cadila, Franco, & Blue Cross have reflected dip in MS for Jun'23 as compared to May'23

IQVIA TSA & SSA Dataset Jun'23 7

 Top Companies #21-30
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

99 SANOFI* 180 -7 89
ALEMBIC 227 4
101 FDC 165 8 104
ERIS* 183 6
8 103 JB PHARMA* 159 12 107
FDC 179
11 106 ERIS* 159 8 104
JB PHARMA* 179
Month

Month
-7 89 HIMALAYA 117 -8 88
HIMALAYA 132
10 106 AJANTA 116 10 106
AJANTA 131
0 95 CADILA 102 3 99
CADILA 123
28 123 LA RENON 100 29 124
LA RENON 122
-9 87 FRANCO 94 -9 87
FRANCO 101
19 114 INDOCO* 86 -5 91
CORONA 101

ALEMBIC 3,119 101 SANOFI* 2,369 -1 90

12
FDC 2,158 106 FDC 1,984 17 106
17
ERIS* 2,155 98 ERIS* 1,871 8 98
8
JB PHARMA* 2,088 109 JB PHARMA* 1,834 20 109
21
MAT

94 3 93

MAT
HIMALAYA 1,640 HIMALAYA 1,466
4
AJANTA 1,542 104 AJANTA 1,363 14 103
15
CADILA 1,539 97 FRANCO 1,345 7 97
7
FRANCO 1,449 97 CADILA 1,264 7 97
8
LA RENON 1,315 114 INDOCO* 1,163 4 95
27
INDOCO* 1,286 95 BLUE CROSS 1,133 8 98
5

• TSA: La Renon has posted the highest growth for the month followed by Corona and for MAT, La Renon has posted highest growth followed by JB Pharma*
• SSA: La Renon has posted highest growth at Month level and for MAT, JB Pharma* has reflected highest growth followed by FDC

IQVIA TSA & SSA Dataset Jun’23 8

 Top Companies #31-40 Market Share Trend
0.75 Val Jun'23 MS Jun'23
(P&G) 87 0.53%
0.70
LA RENON 122 0.74%

0.65 HETERO* 95 0.57%

(MEDLEY) 84 0.51%
0.60 101 0.61%
CORONA
SYSTOPIC 86 0.52%
0.55
BHARAT SERUM 66 0.40%

0.50 H&H 70 0.43%

WIN MEDICARE 71 0.43%

0.45 63 0.38%
MSD*

0.40

0.35

0.30
Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’23 May’23 Jun’23

• La Renon, Hetero*, Corona, Systopic, Bharat Serum, H&H & Win Medicare have shown improvement in MS for Jun'23 as compared to May’23
• MSD* have maintained MS in the month of Jun'23
• P&G, & Medley have reflected dip in MS for Jun'23 as compared to May'23

IQVIA TSA & SSA Dataset Mar’’23 9

 Top Companies #31-40
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

INDOCO* 96 -4 92 CORONA 84 18 114

HETERO* 95 23 118 BLUE CROSS 81 -2 95
BLUE CROSS 89 -2 94 P&G HLTH 79 -6 91
P&G HLTH 87 -5 91 MEDLEY 79 -4 92
Month

Month
SYSTOPIC 86 7 102 SYSTOPIC 77 6 102
MEDLEY 84 -4 92 HETERO* 76 25 121
WIN MEDICARE 71 -1 95 WIN MEDICARE 61 0 96
H&H 70 0 96 H&H 60 -2 94
MEYER 67 5 100 WALLACE 59 7 102
FOURRTS 67 9 104 FOURRTS 58 9 105

BLUE CROSS 1,243 9 98 LA RENON 1,076 29 117

P&G HLTH 1,139 5 95 P&G HLTH 1,038 4 94
HETERO* 1,135 17 106 CORONA 956 21 110
CORONA 1,135 21 109 MEDLEY 935 5 95
MAT

98 17 106

MAT
SYSTOPIC 1,017 8 HETERO* 917
MEDLEY 998 5 95 SYSTOPIC 906 8 98
WIN MEDICARE 917 11 100 WIN MEDICARE 797 11 101
H&H 892 7 97 H&H 773 6 96
FOURRTS 847 12 102 APEX 739 9 99
APEX 835 10 99 FOURRTS 730 11 101

• TSA : Hetero* shows the highest growth for the month followed by Fourrts, while for MAT, Corona has posted highest growth followed by Hetero*
• SSA: Hetero* shows the highest growth for the month followed by Corona, while for MAT, La Renon has posted highest growth followed by Corona

IQVIA TSA & SSA Dataset Jun’23 10

 Top Companies #41-50 Market Share Trend
0.48

0.46 Val Jun'23 MS Jun'23

0.44 BOEHRINGER 61 0.37%
0.42 APEX 60 0.36%

0.40 FOURRTS 67 0.41%

0.38 (JANSSEN) 65 0.39%

0.36 (MEYER ) 67 0.41%

0.34
(NOVARTIS*) 59 0.36%
WALLACE 66 0.40%
0.32
(RAPTAKOS) 60 0.36%
0.30
(CENTAUR) 34 0.21%
0.28
(DABUR) 42 0.25%
0.26

0.24

0.22

0.20
Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’23 May’23 Jun’23

• Boehringer & Wallace have shown improvement in MS for Jun'23 as compared to May'23
• Apex & Fourrts have maintained MS in the month of Jun’23
• Janssen, Meyer, Novartis*, Raptakos, Centaur & Dabur have reflected dip in MS for Jun'23 as compared to May'23

IQVIA TSA & SSA Dataset Jun'23 11

 Top Companies #41-50
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

8 MEYER 57 6 102
WALLACE 66 103
0 APEX 53 -5 91
BHARAT SERUM 66 96
-8 RAPTAKOS 52 -5 92
JANSSEN 65 88
1 BOEHRINGER 51 -7 90
MSD* 63 97
Month

Month
-8 PHARMED 47 17 113
BOEHRINGER 61 88
-6 BHARAT SERUM 47 -3 93
APEX 60 90
-3 MSD* 44 -6 91
RAPTAKOS 60 93
-8 NOVARTIS* 44 -5 91
NOVARTIS* 59 88
18 JANSSEN 44 -8 89
SAMARTH 55 113
16 WOCKHARDT* 42 17 112
PHARMED 55 111

JANSSEN 799 6 96 WALLACE 709 10 100

MEYER 793 8 98 MEYER 680 9 99
WALLACE 793 11 100 RAPTAKOS 634 9 99
BHARAT SERUM 780 -6 85 BOEHRINGER 597 -7 84
MAT

MAT
NOVARTIS* 759 5 95 NOVARTIS* 580 99
MSD* 740 -6 85 JANSSEN 567 3 93
RAPTAKOS 723 11 100 CENTAUR 562 4 94
BOEHRINGER 722 -5 86 BHARAT SERUM 560 -9 83
ASTRA 643 20 109 MSD* 533 -11 81
SAMARTH 624 19 107 PHARMED 519 16 105

• TSA: Samarth is the fastest growing company for the month followed by Pharmed and for MAT, Astra has posted highest growth followed by Samarth

• SSA: Pharmed & Wockhardt is the fastest growing company for the month while for MAT, Pharmed is the fastest growing company followed by Wallace

IQVIA TSA & SSA Dataset Jun’23 12

 Top 40 Brands
TSA

Value % Gwth Value

%MS % Gwth % MS
(Rs. Crs) (Rs. Crs)

3 0.45 0.21
MIXTARD 74 NOVOMIX 34 -11
8 0.42 0.20
GLYCOMET-GP 69 ACILOC 34 5
13 0.38 0.20
FORACORT 63 ROSUVAS 33 20
Top 1-10

Top 21-30
14 0.32 0.20
THYRONORM 53 ULTRACET 33 0
0 0.29 0.20
AUGMENTIN 47 CILACAR 32 26
1 0.29 0.19
PAN 47 DUPHASTON 32 -5
32 0.28 0.19
RYZODEG 45 T-BACT 31 22
39 0.27 0.19
ELECTRAL 44 LEVIPIL 31 7
-15 0.26 0.19
LIV-52 43 ECOSPRIN-AV 31 16
10 0.26 0.18
PAN-D 43 VOLINI 30 3
0.25 30 0.18
UDILIV 41 11 DUOLIN 4
DEXORANGE 40 -6 0.24 RANTAC 29 -3 0.17
0.24 0.17
Top 11-20

ZERODOL-SP 39 14 GEMER 29 10

Top 31-40
MANFORCE 39 22 0.24 JANUMET 28 -14 0.17
BETADINE 39 -7 0.24 PANTOP 28 7 0.17
CLAVAM 37 5 0.23 BECOSULES 28 -12 0.17
MONOCEF 37 -9 0.22 CALPOL 27 -10 0.16
LANTUS 36 -30 0.22 MIKACIN 27 -11 0.16
SHELCAL 36 -3 0.22 DOLO 27 13 0.16
TELMA 34 10 0.21 PANTOP-D 26 6 0.16

• Mixtard is the topmost brand with 74 Crs of sales & MS of ~0.45% for the month

• Among top 10 brands Electral has shown highest growth followed by Ryzodeg for the month

IQVIA TSA & SSA Dataset Jun’23 13

 Star Brands of the month
TSA
Movers & Shakers TSA: Products

Among the Top 25 products as per Jun'23 Month (in comparison to May'23 Month)

• Mixtard has maintained No 1 position at month level with a growth of 3%

• Amongst the top 10 Brands, highest growth is observed by Electral with a growth of 39%
• Augmentin, Pan & Udiliv gained 2 ranks to secure 5th , 6th & 11th position with a growth of 0%, 1% & 11% each respectively
• Ryzodeg gained 3 ranks to secure 7th position with a growth of 32%
• Electral gained 4 ranks to secure 8th position with a growth of 39%
• Zerodol SP gained 5 ranks to secure 13th position with a growth of 14%
• Novomix gained 1 rank to secure 21st position
• Telma gained 6 ranks to secure 20th position with a growth of 10%
• Pan-D & Cilacar gained 7 ranks to secure 10th & 25th position with a growth of 10% & 26% each respectively

IQVIA TSA & SSA Dataset Jun’23

14
 Highlight
TSA SSA
Movers & Shakers TSA: Companies Movers & Shakers SSA: Companies

In the month of Jun'23 (in comparison to May'23), among the In the month of Jun'23 (in comparison to May'23), among
Top 25 companies the Top 25 companies
• Sun* has maintained its top position in the IPM with a market • Sun* has maintained its top position in the IPM with a market
share of 8% share of 8%
• Torrent*, DRL, USV, Glenmark, Micro* & Eris* improved by 1 • Intas*, DRL, USV, Glenmark & JB Pharma* improved by 1
rank each to reach 7th,10th,14th,16th,18th & 22nd positions, rank each to reach 7th,10th,13th,15th & 23rd position,
respectively respectively

IQVIA TSA & SSA Dataset Jun’23 15

 Indian / MNC trends % Growth Over Same Month Last Year Indian MNC

30
26
25
21
20 17
16
Month Growth

14 15
15 12
11 10 10
10
10 8 8 9
7 7
4 5
5 4
4 2
4 2
0 2
JUL’22 AUG’22 SEP’22 OCT’22 NOV’22 DEC’22 JAN’23 FEB’23 MAR’23 APR’23 MAY’23 JUN’23

Value (Rs. Crs)

Indian MNC

16,716 17,652 17,624 16,289 17,378 17,168 16,621 16,709 17,165 17,842 17,112 16,469
Share in IPM

13,867 14,627 14,668 13,512 14,405 14,234 13,825 13,893 14,176 14,775 14,168 13,653

2,849 3,025 2,956 2,777 2,973 2,935 2,795 2,815 2,990 3,066 2,944 2,816

JUL’22 AUG’22 SEP’22 OCT’22 NOV’22 DEC’22 JAN’23 FEB’23 MAR’23 APR’23 MAY’23 JUN’23

• Indian companies has registered growth of 5% whereas MNC’s registered a growth of 2% for the month

IQVIA TSA & SSA Dataset Jun'23 16

 Acute / Chronic Trends
ACUTE CHRONIC
30
27
25 22
20
20
1614 15
Growth (%)

15 13 13 12 12
10 11 13 11 10
8 9 8 8
10 7
4 3
5 1
0
0
-5
JUL’22 AUG’22 SEP’22 OCT’22 NOV’22 DEC’22 JAN’23 FEB’23 MAR’23 APR’23 MAY’23 JUN’23

Gwth % 4.97% 2.98% 6.64% -0.61% 4.01%

Top 5 TC 4s

276
Value (Rs 203
177 159
Crs) 130

GLIMEPIRIDE+METFORM. INTER.-ACTING+FAST ACTING FOOD SUPPLEMENTS AMOXY. & CLAV. SOLIDS PANTOPR.+ DOMPERID.

Value (Rs. Crs)

Top 3 Cos. in TC4

USV 69 ABBOTT* 153 APEX 27 GSK* 34 ALKEM* 44

SUN* 29 LUPIN 24 ALKEM* 27 ALKEM* 28 ARISTO* 26

LUPIN 29 CIPLA 9 SUN* 21 MANKIND 22 SUN* 20

• Acute has shown growth of 3% whereas Chronic has shown growth of 8% for the month

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Jun'23 17
 Top Therapy Trends
TSA

Value_Jun'23 (Rs. Crs) % Gwth SPLY Value_Jun'23 (Rs. Crs) % Gwth SPLY

C10A041 ROSUVASTATIN 112 10 J01C0G1 AMOXY. & CLAV. SOLIDS 159 -1

C02C042 TELMISARTAN 90 5 J01N013 MEROPENEM 113 20

16 J01D0C2 CEFTRIAXONE INJECTABLS 96 -5

Anti-Infectives
C02F063 AMLODIPINE+TELMISARTAN 83
C02G0H5 TELMISARTAN + HCT 70 7 J01D0L6 CEFIXIME ORAL SOL. 62 -13
Cardiac

C10A034 ATORVASTATIN 69 -8 J01D0Z7 CEFTRIAXONE+SULBACTAM 62 5

B01A0E6 ENOXAPARIN 63 13 J01K0310 AMIKACIN 62 -9

C01D0B9 CILNIDIPINE 59 19 J01K05 PIPERACILLIN+TAZOBACTAM 60 9

C02F028 ATENOLOL+AMLODIPINE 55 8 J01C0H4 AMOXY. & CLAV. LIQUIDS 57 -5

C01E037 METOPROLOL 53 -4 J01F045 AZITHROMYCIN ORAL SOLIDS 55 -13

C02F0I METOPROLOL+TELMISARTAN 53 12 J01D0I8 CEFUROXIME ORAL SOLIDS 54 -17

A02B0Q1 PANTOPR.+ DOMPERID. 130 4 A10B0Q1 GLIMEPIRIDE+METFORM. 276 5

A02B0R2 RABEPRA.+ DOMPERID. 99 2 A10C032 INTER.-ACTING+FAST ACTING 203 3
A07L014 ORAL ELECTROLYTES 98 27 A10B0B3 GLIMEPIRIDE+METFOR+VOGLIB 104 7
3

Anti Diabetic
A02B0A3 PANTOPRAZOLE SOLIDS 94 A10C054 LONG ACTING 80 -9
A07K095 OTHERS 61 3 A10B0D5 METFORMIN + VILDAGLIPTIN 77 -7
GI

A02B0S7 ESOMEPR.+ DOMPERID. 56 8 A10C016 FAST ACTING 73 12

A02B016 RANITIDINE ORAL SOLIDS 55 -2 A10B078 METFORMIN + SITAGLIPTIN 62 12
A02A059 ANTACID+ANTIFLATU.LIQ 52 12 A10B0W7 PIOGLITAZ.+METFORM.+GLIM. 62 1
A09A028 DIGEST. INC. ENZYME LIQUIDS 50 -5 A10B1210 DAPAGLIFLOZIN 48 13
A06A07 MILK OF MAG AND COMB. 48 6 A10B0O9 METFORMIN + TENELIGLIPTIN 44 -16

• In Cardiac, Cilnidipine posted highest growth of 19%

• In AI, Meropenem has posted 20% growth which is highest amongst top therapies
• Oral Electrolytes is the top contributing subgroup in GI therapy with value of around 98 Cr growing at 27%
• In Anti diabetic, Dapagliflozin has posted highest growth of 13%
IQVIA TSA & SSA Dataset Jun’23
18
 Top Therapy Trends
TSA

Value_Jun'23 (Rs. Crs) % Gwth SPLY Value_Jun'23 (Rs. Crs) % Gwth SPLY

V06E011 FOOD SUPPLEMENTS 177 7 R05B011 COUGH PREP. ETHICALS 108 -17
A12A042 CALCIUM + COLECALCI. SOLI. 105 3 R03C0R2 FORMOTERAL+BUDESONIDE 103 18
A11F023 MECOBALAMIN COMB. 100 -2 R03B013 LEVOCETIRIZ.+MONTELU SOLD 71 -5

Respiratory
V06C014 INFANT FORMULAS 96 28 R05A025 COLD PREP. LIQUIDS 45 -22
VMN

A11C025 PLAIN VIT.D 85 8 R05B054 LEVOSALBUTAMOL & COMB. 39 -12

A11A046 OTH. MULTIVIT.-MIN. SOLIDS 71 8 R03C0S8 IPRATROPIUM + LEVOSALBU. 35 5
A12A018 CALCIUM ORAL SOLIDS 49 5 R05B076 CHLORPHNMN+DEXTROMETHRPHN 33 -6
A15A017 APPETITE STIMULANTS 47 -11 R03C0P SALMETEROL+FLUTICASONE 29 -17
A11F05 MECOBALAM.+COLECALI. COMB 38 11 R03C0210 BUDESONIDE 29 -4
V06E059 ADULT WELLNESS 37 -8 R05A017 COLD PREP. SOLIDS 27 -16

M02A011 NSAIDS 84 2 D02A011 EMOLLIENTS,PROTECTIVES 117 18

M05C023 CALCITRIOL COMB. 75 -2 D01C032 ITRACONAZOLE 73 -2
M01A0G4 PARACE.+ACECLOF.+SERRAPE. 68 14 D11A093 OTH.DERMATOLOGICAL PREP. 59 14
N02B052 PARACETAMOL ORAL SOLIDS 53 0 D02B016 SUNSCREENS 41 36

Derma
M05B0C8 COLLAGEN COMB 46 15 D06A084 MUPIROCIN 41 15
Pain

N02B0K6 PARACETAMOL + TRAMADOL 45 0 D01A04 CLOTRIMAZOLE 36 26

N02B079 PARACETAMOL INJECTIONS 39 2 D07D0C7 CLOBET+MICONAZOL+NEOMYCIN 36 21
M01A0U7 ACECLOFENAC + PARACETAMOL 38 -3 D01A025 LULICONAZOLE 33 -13
N02B065 PARACETAMOL ORAL LIQUIDS 35 -17 D16A0D8 OTH HAIR CARE PREPS. 31 19
M01A0310 DICLOFENAC INJECTABLES 34 -1 D02C079 HYDROQU.+TRETI.+MOMETA. 26 -4

• In VMN therapy, food supplements is the top contributing subgroup with 177 Cr of sales posted growth of 7%
• In Respiratory market, Formoteral + Budesonide posted highest growth of 18%
• In Pain market, Paracetamol+Aceclof+Serra combination posted 14% growth
• Emollients protectives registered highest sales of 117 Cr in derma market with 18% growth while the highest growth of 36% is observed in Sunscreens

IQVIA TSA & SSA Dataset Jun’23

19
Top Therapy Trends
TSA

Value_Jun'23 (Rs. Crs) Value_Jun'23 (Rs. Crs) % Gwth SPLY

% Gwth SPLY
6 B03A011 CONV.IRON SOLIDS 123 1
N03A0T1 LEVETIRACETAM 83
7 B03A022 CONV.IRON LIQUID 107 -6
N06C022 ESCITALOPRAM+CLONAZEPAM 41
14 G03D043 DYDROGESTERONE 97 19
N03A0V3 GABAPENTIN + NORTRIPTYLIN 38
9 76 2
Neuro / CNS

G03D034 PROGESTERONE

Gynaec.
N07C014 BETAHISTINE 37
5 B03A035 CONV.IRON INJ. 70 6
N03A0J6 OXCARBAZEPINE 26
-3 G03K026 MIFEPRISTONE+MISOPROSTOL 41 16
N07A027 PREGABALIN+MECOBALAMIN 25
4 G02C017 OTHER GYNAECO.PREP. 33 2
N03A0I9 NORTRIPTYLINE+PREGABALIN 24
-3 G03G068 HUMAN MENOPAUSAL GONADOTROP. 33 19
N07A018 PREGABALIN 24
-10 G03G059 HUMAN CHORIONIC GONADOTROP. 27 7
N03A045 SODIUM VALPROATE ORAL SOLIDS 22
23 G03D0210 NORETHISTERONE 21 0
N07A0A MECOBLMN+NORTRPTN+PREGBLN 20

• In Neuro therapy, levetiracetam is the top valued subgroup with 83 Crs of sales and 6% growth while Gaba+Nortriptylin growth was at 14%

• Amongst the top Gynae therapies, Dydrogesterone & Human Menopausal Gonadotrop.has posted highest growth of 19%

IQVIA TSA & SSA Dataset Jun’23

20
Key changes
PTR Changes (Top 50 brands) New Introduction

➢ Total number of SKUs with PTR changes in Jun'23 are 2799 ➢ 1273 new packs were Introduced in Jun'23
➢ Among the top 50 brands of the industry, PTR changes reflected in
SKUs of the following brand-Foracort, Thyronorm, Pan, Electral, Liv-52,
Manforce, Clavam, Monocef, Lantus, Rosuvas, T-Bact, Levipil, Duolin,
Gemer, Calpol, Mikacin, Dolo, Gluconorm-G, Duphalac, Susten,
Azithral, Zifi

New Lab & Corporate Brand Transfer

➢ 19 Corporates & Labs were introduced in Jun'23 dataset 75 brand transfers registered in Jun'23

IQVIA TSA & SSA Dataset Jun'23 21

THANK YOU

22